ArticleNutrition & diabetes2026
Insulin resistance drives GGT elevation in MASLD with diabetes: evidence from clinical cohorts, mendelian randomization and functional genomics.
Article in Nutrition & diabetes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes (T2D) commonly occur together and are linked by shared factors like insulin resistance and excess liver fat. While enzymes such as ALT and AST are routinely measured in these conditions, the clinical significance of gamma-glutamyl transferase (GGT) remains less well understood.
objectiveTo investigate the relationship between GGT, insulin resistance, and MASLD using integrative approaches combining clinical data, Mendelian Randomization (MR), and functional genomics.
methodA hospital-based cohort (N = 498) was analyzed for MASLD and T2D status alongside liver enzymes and insulin resistance (HOMA-IR). Findings were validated in the NHANES 2017-2020 dataset (N = 2586). Univariable and multivariable MR analyses were performed using GWAS summary statistics for fasting insulin, glycemic traits, and percentage liver fat to assess their potential causal effects on GGT. Functional annotation of GGT-associated variants was conducted using FUMA.
resultsIndividuals with both MASLD and T2D exhibited significantly elevated GGT and HOMA-IR levels compared to those with either condition alone. MR analyses demonstrated a potential causal effect of genetically predicted fasting insulin on GGT, independent of other metabolic traits. Functional enrichment analysis revealed involvement of insulin signaling and lipid metabolism pathways. Tissue expression highlighted predominant liver and pancreatic expression of GGT-associated genes.
conclusionThese findings suggest that insulin resistance may contribute more strongly to GGT elevation in MASLD than hepatic fat accumulation, though the comparatively weak instrument strength for liver fat in the multivariable model warrants cautious interpretation of this comparison. Genetically predicted fasting insulin showed a potential causal effect on GGT independent of other metabolic traits. GGT appears to reflect underlying metabolic dysfunction, particularly insulin resistance; however, further prospective and interventional studies are required before its role as a predictive or clinically actionable biomarker can be established.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.